OBI announced last week that it had entered into an exclusive distribution agreement with Mölnlycke Health care (MHC) for Steriwave in the UK, EU and Middle East markets. The MHC collaboration should help drive revenue growth in the near term and in our view MHC is a quality strategic partner, with excellent geographical reach and good existing penetration within the NHS. We believe MHC is fully aligned with OBI, especially given Steriwave complements MHC’s Hibiwash skin preparation line. Ultimately, we believe there is significant scope to drive revenues, margin improvement and profitability over the next 2-3 years.